Overview

An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort

Status:
Completed
Trial end date:
2017-08-24
Target enrollment:
Participant gender:
Summary
This is an open label, long-term extension study in approximately 24 male DMD subjects consisting of children (ages 4-12, inclusive) and adolescents (ages 13-16, inclusive) who participated in the MP-104-CL-005 PK study.
Phase:
Phase 1
Details
Lead Sponsor:
Marathon Pharmaceuticals, LLC
PTC Therapeutics
Treatments:
Deflazacort